Resilience allocates $225M to expand manufacturing capacity in Cincinnati
20 Feb 2024
National Resilience is working to expand its clinical and commercial drug manufacturing capabilities to provide more than 200 million units to its clients by 2025.
Resilience plans to invest at least $225 million into its Cincinnati site, which is dedicated to filling vials, cartridges and pre-filled syringes, a company release states. The number of high-speed fill lines should increase from three to four by 2025, while the number of device assembly and packaging suites should grow to six.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.